AACR logo

More articles from Therapeutic Agents: Other: Poster Presentations - Proffered Abstracts

Abstract C041: Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancer
Dwan-Ying Chang, Chia-Chi Lin, Tom Wei-Wu Chen, Ching-Hung Lin, Jih-Hsiang Lee, Ta-Chung Chao, Chun-Yu Liu, Issei Achiwa, Emi Kamiyama, Yasuyuki Okuda, Caleb Lee, Yee Chao

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C041; DOI: 10.1158/1535-7163.TARG-19-C041
Abstract C047: A phase Ia/Ib, dose-escalation/expansion study of BI 907828, an MDM2-p53 antagonist, in combination with BI 754091, an anti-PD-1 antibody, and BI 754111, an anti-LAG-3 antibody, in patients with advanced solid tumors
Anthony Tolcher, Navid Hafez, Noboru Yamamoto, Jaehong Park, Rolf Grempler, Anthony Lucarelli, Markus P Vallaster, Bushi Wang, David Hyman

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C047; DOI: 10.1158/1535-7163.TARG-19-C047
Abstract C051: MDM2 inhibitor KRT-232 extends survival in glioblastoma patient-derived xenograft models
Ann C Mladek, Shiv Gupta, Minjee Kim, Afroz Shareef Mohammad, Katrina K Bakken, Helen He, Zeng Hu, Danielle M Burgenske, Brett L Carlson, William F Elmquist, Jann Sarkaria

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C051; DOI: 10.1158/1535-7163.TARG-19-C051
Abstract C055: Novel imipridone ONC206 inhibits cell proliferation and induces apoptosis in uterine serous cancer through altering MAPK/AKT/AMPK signaling network and metabolic reprogramming
Chi Lam Au Yeung, Wen Hu, Li Zhang, Sammy Ferri-Borgogno, Rohinton Tarapore, Karen H Lu, Samuel C Mok

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C055; DOI: 10.1158/1535-7163.TARG-19-C055
Abstract C035: A FoxM1-autoregulation motif serves as an inhibitor to suppress cellular vitality of NSCLC
Chia-Chan Hsu, I-Ching Wang

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C035; DOI: 10.1158/1535-7163.TARG-19-C035
Abstract C040: INTH-454, a p300/CBP interactome modulator, targets multiple pathogenesis factors in solid tumors and induces strong anti-proliferative effects in vitro and in vivo as single agent
Valentino Cattori, Bernd Hentsch, Ulrich Kessler

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C040; DOI: 10.1158/1535-7163.TARG-19-C040
Abstract C038: Targeting aberrant pathways by an advanced combination regimen to effectively and safely control urothelial carcinoma
Hwa-Chain Wang, Pawat Pattarawat, Shelby Wallace, Robert Donnell

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C038; DOI: 10.1158/1535-7163.TARG-19-C038
Abstract C037: Anti-metastatic effect of PLAG via interference of neutrophil elastase/PAR2/EGFR signaling on A549 lung cancer orthotopic implantation model
GUEN TAE KIM, SUN YOUNG YOON, KI-YOUNG SOHN, MYUNG-HWAN KIM, JAE WHA KIM

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C037; DOI: 10.1158/1535-7163.TARG-19-C037
Abstract C062: The use of nanoparticles to improve tumour radiosensitivity
Ben Reed, Gareth Wakefield, Matt Stock, Gregory Tudor

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C062; DOI: 10.1158/1535-7163.TARG-19-C062
Abstract C050: A novel, potent, and selective hypoxia-inducible factor (HIF)-2α antagonist
Kelsey E Sivick Gauthier, Kenneth V Lawson, Dana Piovesan, Matthew J Walters, Ada Chen, Xiaoning Zhao, Cesar Meleza, Nikki Kimura, Tim Park, Steve Young, Anh Tran, Samuel L Drew, Lixia Jin, Manmohan Leleti, Elaine Ginn, Jay P Powers

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C050; DOI: 10.1158/1535-7163.TARG-19-C050

Main menu

User menu

Search

More articles from Therapeutic Agents: Other: Poster Presentations - Proffered Abstracts

Pages

Articles

Info for

About MCT